Analyst Research

Report Title Price
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Recordati Industria Chimica E Farmaceutica SpA Concludes Acquisition of Portfolio of Products in the United States


Monday, 21 Jan 2013 02:45am EST 

Recordati Industria Chimica E Farmaceutica SpA announced that it has concluded the acquisition of all rights concerning a portfolio of products indicated for the treatment of rare and other diseases and marketed mainly in the United States of America, from Lundbeck LLC. The value of the transaction is of USD 100 million, of which USD 80 million were paid at the closing. The acquired portfolio will be marketed in the United States by Recordati Rare Diseases, a wholly-owned US corporation. The main products in the portfolio is Panhematin (haemin for injection) for the amelioration of recurrent attacks of acute intermittent porphyria. Other drugs acquired are NeoProfen (ibuprofen lysine injection) and Indocin I.V. (indomethacin injection), indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants, and Cosmegen (dactinomycin for injection) used mainly in the treatment of three rare cancers. 

Related Company News

Company Quote